Evidence map›Paper›PMID 42909761›Full record

ArticleHepatology international2026

Higher relapse rate after stopping tenofovir alafenamide compared with entecavir; but not tenofovir disoproxil fumarate in HBeAg-positive patients.

Kuan-Hung Wan, Cheng-Yuan Peng, Yuan-Hung Kuo, Tsung-Hui Hu, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu, Chien-Hung Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kuan-Hung WanDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.
Cheng-Yuan PengCenter for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Yuan-Hung KuoDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.
Tsung-Hui HuDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.
Jing-Houng WangDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.
Chao-Hung HungDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.
Sheng-Nan LuDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.
Chien-Hung ChenDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan. e580306@ms31.hinet.net.ORCID http://orcid.org/0000-0002-8896-8133

Funding

Chang Gung Memorial Hospital CMRPG8N0981Ministry of Science and Technology NMRPG8L6121
6 · The paper itself

Abstract

background/purposeThis study compares the hepatitis B virus (HBV) relapse rates after discontinuation of entecavir, tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF) therapy in HBeAg-positive patients.

methodsThis study was a retrospective analysis of a prospectively collected cohort comprising 427 HBeAg-positive patients without cirrhosis who received entecavir (n=200), TDF (n=133), or TAF (n=94) were enrolled. All patients met the Taiwan National Health Insurance stopping criteria for antiviral therapy.

resultsAt 156 weeks, the cumulative incidences of virological relapse and clinical relapse, and retreatment were higher in the off-TAF group (85.3%, 73.7%, and 76.6%, respectively) than in the off-entecavir group (58.0%, 45.5%, and 38.9%, respectively) (all p <0.001). Compared with the off-TDF group (74.6%, 64.4%, and 58.8%, respectively), the off-TAF group showed comparable rates of virological relapse (p=0.139) but significantly higher rates of clinical relapse (p=0.042) and retreatment (p=0.003). The median time to clinical relapse was earlier in patients discontinuing TAF than in those discontinuing entecavir or TDF (17, 42, and 24 weeks, respectively). Multivariable analysis demonstrated that TAF therapy was an independent risk factor for virological relapse, clinical relapse, and retreatment compared with entecavir, but not with TDF; these findings remained consistent after propensity score matching. Among patients with clinical relapse, HBeAg seroreversion was more frequent in the off-TAF group than in the off-entecavir (73.0% vs. 51.4%, p <0.001) and off-TDF groups (73.0% vs. 56.8%, p=0.029).

conclusionsDiscontinuation of TAF therapy was associated with earlier and higher HBV relapse rates compared with entecavir, but not TDF, in HBeAg-positive patients.

Indexed as

Alanine aminotransferaseChronic hepatitis BEnd of treatmentHBcrAgHBeAgHBsAgHBVNaïveNucleos(t)ide analoguePropensity score matching

Identifiers

PMID42909761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.